Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram.
Elevated plasma levels of asymmetric dimethylarginine (ADMA) have been reported to be associated with endothelial dysfunction, inflammation, and oxidative stress in multiple cardiovascular diseases. This study aimed to investigate whether ADMA was a predictor of clinical outcomes in atrial fibrillat...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3737156?pdf=render |
id |
doaj-f89ce333e32c4ba5adfed8fa88b4edd8 |
---|---|
record_format |
Article |
spelling |
doaj-f89ce333e32c4ba5adfed8fa88b4edd82020-11-24T22:25:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0188e7167510.1371/journal.pone.0071675Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram.Tze-Fan ChaoTse-Min LuYenn-Jiang LinHsuan-Ming TsaoShih-Lin ChangLi-Wei LoYu-Feng HuTa-Chuan TuanMing-Hsiung HsiehShih-Ann ChenElevated plasma levels of asymmetric dimethylarginine (ADMA) have been reported to be associated with endothelial dysfunction, inflammation, and oxidative stress in multiple cardiovascular diseases. This study aimed to investigate whether ADMA was a predictor of clinical outcomes in atrial fibrillation (AF).From 2006-2009, 990 individuals were referred to our institution for coronary angiography. Among these patients, 141 subjects with a diagnosis of AF, including 52 paroxysmal AF (PAF) and 89 non-paroxysmal AF (non-PAF) patients, were identified as the study population. Plasma ADMA levels were measured. An adverse event was defined as the occurrence of ischemic stroke or cardiovascular death. The ADMA levels were higher in AF than non-AF patients (0.50 ± 0.13 versus 0.45 ± 0.07 µmol/L; p<0.001). Besides, non-PAF patients had higher ADMA levels than PAF patients (0.52 ± 0.15 versus 0.48 ± 0.08 µmol/L; p<0.001). During the follow-up of 30.7±14.4 months, 21 patients (14.9%) experienced adverse events, including cardiovascular death in 7 patients and ischemic stroke in 14. ADMA level, CHA2DS2-VASc score, and left atrial diameter were independent predictors of adverse events in the multivariate analysis. At a cutoff-value of 0.55 µmol/L, the Kaplan-Meier survival analysis showed that patients with a high ADMA level had a higher event rate during the follow-up period.A higher level of ADMA was a risk factor of adverse events in AF patients, which was independent from the CHA2DS2-VASc score. It deserves to further study whether ADMA could potentially refine the clinical risk stratification in AF.http://europepmc.org/articles/PMC3737156?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tze-Fan Chao Tse-Min Lu Yenn-Jiang Lin Hsuan-Ming Tsao Shih-Lin Chang Li-Wei Lo Yu-Feng Hu Ta-Chuan Tuan Ming-Hsiung Hsieh Shih-Ann Chen |
spellingShingle |
Tze-Fan Chao Tse-Min Lu Yenn-Jiang Lin Hsuan-Ming Tsao Shih-Lin Chang Li-Wei Lo Yu-Feng Hu Ta-Chuan Tuan Ming-Hsiung Hsieh Shih-Ann Chen Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. PLoS ONE |
author_facet |
Tze-Fan Chao Tse-Min Lu Yenn-Jiang Lin Hsuan-Ming Tsao Shih-Lin Chang Li-Wei Lo Yu-Feng Hu Ta-Chuan Tuan Ming-Hsiung Hsieh Shih-Ann Chen |
author_sort |
Tze-Fan Chao |
title |
Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. |
title_short |
Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. |
title_full |
Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. |
title_fullStr |
Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. |
title_full_unstemmed |
Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. |
title_sort |
plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
Elevated plasma levels of asymmetric dimethylarginine (ADMA) have been reported to be associated with endothelial dysfunction, inflammation, and oxidative stress in multiple cardiovascular diseases. This study aimed to investigate whether ADMA was a predictor of clinical outcomes in atrial fibrillation (AF).From 2006-2009, 990 individuals were referred to our institution for coronary angiography. Among these patients, 141 subjects with a diagnosis of AF, including 52 paroxysmal AF (PAF) and 89 non-paroxysmal AF (non-PAF) patients, were identified as the study population. Plasma ADMA levels were measured. An adverse event was defined as the occurrence of ischemic stroke or cardiovascular death. The ADMA levels were higher in AF than non-AF patients (0.50 ± 0.13 versus 0.45 ± 0.07 µmol/L; p<0.001). Besides, non-PAF patients had higher ADMA levels than PAF patients (0.52 ± 0.15 versus 0.48 ± 0.08 µmol/L; p<0.001). During the follow-up of 30.7±14.4 months, 21 patients (14.9%) experienced adverse events, including cardiovascular death in 7 patients and ischemic stroke in 14. ADMA level, CHA2DS2-VASc score, and left atrial diameter were independent predictors of adverse events in the multivariate analysis. At a cutoff-value of 0.55 µmol/L, the Kaplan-Meier survival analysis showed that patients with a high ADMA level had a higher event rate during the follow-up period.A higher level of ADMA was a risk factor of adverse events in AF patients, which was independent from the CHA2DS2-VASc score. It deserves to further study whether ADMA could potentially refine the clinical risk stratification in AF. |
url |
http://europepmc.org/articles/PMC3737156?pdf=render |
work_keys_str_mv |
AT tzefanchao plasmaasymmetricdimethylarginineandadverseeventsinpatientswithatrialfibrillationreferredforcoronaryangiogram AT tseminlu plasmaasymmetricdimethylarginineandadverseeventsinpatientswithatrialfibrillationreferredforcoronaryangiogram AT yennjianglin plasmaasymmetricdimethylarginineandadverseeventsinpatientswithatrialfibrillationreferredforcoronaryangiogram AT hsuanmingtsao plasmaasymmetricdimethylarginineandadverseeventsinpatientswithatrialfibrillationreferredforcoronaryangiogram AT shihlinchang plasmaasymmetricdimethylarginineandadverseeventsinpatientswithatrialfibrillationreferredforcoronaryangiogram AT liweilo plasmaasymmetricdimethylarginineandadverseeventsinpatientswithatrialfibrillationreferredforcoronaryangiogram AT yufenghu plasmaasymmetricdimethylarginineandadverseeventsinpatientswithatrialfibrillationreferredforcoronaryangiogram AT tachuantuan plasmaasymmetricdimethylarginineandadverseeventsinpatientswithatrialfibrillationreferredforcoronaryangiogram AT minghsiunghsieh plasmaasymmetricdimethylarginineandadverseeventsinpatientswithatrialfibrillationreferredforcoronaryangiogram AT shihannchen plasmaasymmetricdimethylarginineandadverseeventsinpatientswithatrialfibrillationreferredforcoronaryangiogram |
_version_ |
1725756554997661696 |